Intraocular caspofungin: In vitro safety profile for human ocular cells

Mycoses

Volumn 54, Issue 4, 2011, Pages

  Kernt, M ^a   Kampik, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amphotericin B; Caspofungin; Echinocandins; Fungal endophthalmitis; Intravitreal drug delivery; Voriconazole

Indexed keywords

CASPOFUNGIN; HYDROGEN PEROXIDE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANDIDA; CANDIDA ENDOPHTHALMITIS; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORNEA CELL; DRUG CYTOTOXICITY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; TRABECULAR MESHWORK;

ADULT; AGED; ANTIFUNGAL AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORNEA; ECHINOCANDINS; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; MIDDLE AGED; RETINAL PIGMENT EPITHELIUM; TETRAZOLIUM SALTS; TRABECULAR MESHWORK;

CANDIDA;

EID: 79959269008     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01853.x     Document Type: Article

References (52)

1. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137: 820-5.
2. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Available data on blindness (update 1994). Ophthalmic Epidemiol 1995; 2: 5-39.
3. Thomas PA. Mycotic keratitis - an underestimated mycosis. J Med Vet Mycol 1994; 32: 235-56.
4. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol 2001; 132: 244-51.
5. Brod RD, Flynn HW Jr, Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology 1990; 97: 666-72. disc: 672-4.
6. Essman TF, Flynn HW Jr, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 185-94.
7. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
8. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol 1973; 76: 578-83.
9. Agarwal MB, Rathi SA, Ratho N, Subramanian R. Caspofungin: a major breakthrough in treatment of systemic fungal infections. J Assoc Physicians India 2006; 54: 943-8.
10. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805-12.
11. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-40.
12. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002; 45(Suppl. 3): 56-60.
13. Durand ML, Kim IK, D'Amico DJ et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140: 552-4.
14. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40: e46-8.
15. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: e27-8.
16. Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol 2007; 245: 825-33.
17. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113: 1184-6.
18. Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24: 245-8.
19. Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 2009; 258: 84-93.
20. Kernt M, Neubauer AS, Liegl RG et al. Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 2009; 28: 553-61.
21. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-52.
22. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
23. Feys J, Emond JP, Salvanet-Bouccara A, Dublanchet A. Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J Fr Ophthalmol 1994; 17: 634-9.
24. Sebag J. Anatomy and pathology of the vitreo-retinal interface. Eye 1992; 6(Pt 6): 541-52.
25. Bourne WM, Kaufman HE. The endothelium of clear corneal transplants. Arch Ophthalmol 1976; 94: 1730-2.
26. Bednarz J, Teifel M, Friedl P, Engelmann K. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol Scand 2000; 78: 130-6.
27. Laurell CG, Lydahl E. Evaluation of aqueous outflow facility in patients with high intraocular pressure after cataract surgery. Ophthalmic Surg Lasers Imaging 2006; 37: 476-80.
28. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29: 362-70.
29. Kernt M, Welge-Lussen U, Yu A, Neubauer AS, Kampik A. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007; 104: 965-71.
30. Kernt M, Neubauer AS, Ulbig MW, Kampik A, Welge-Lussen U. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 2008; 34: 480-8.
31. Mo JS, Streilein JW. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001; 31: 3806-15.
32. Satofuka S, Ichihara A, Nagai N et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 2006; 47: 2686-92.
33. Thomas J, Kanangat S, Rouse BT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res 1998; 18: 681-90.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
35. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. Voriconazole in the management of Alternaria keratitis. Cornea 2006; 25: 242-4.
36. Reddy PS, Satyendran OM, Satapathy M, Kumar HV, Reddy PR. Mycotic keratitis. Indian J Ophthalmol 1972; 20: 101-8.
37. Srinivasan M, Gonzales CA, George C et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol 1997; 81: 965-71.
38. Upadhyay MP, Karmacharya PC, Koirala S et al. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol 1991; 111: 92-9.
39. Keswani T, Ahuja V, Changulani M. Evaluation of outcome of various treatment methods for endogenous endophthalmitis. Indian J Med Sci 2006; 60: 454-60.
40. Schiedler V, Scott IU, Flynn HW Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004; 137: 725-31.
41. Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115: 1501-7.
42. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
43. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-5.
44. Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
45. Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-23.
46. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
47. Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997; 41: 2339-44.
48. Schafer-Korting M, Korting HC, Rittler W, Obermuller W. Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection 1995; 23: 292-7.
49. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997; 41: 2326-32.
50. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44: 760-3.
51. Giese MJ, Sumner HL, Berliner JA, Mondino BJ. Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 1998; 39: 2785-90.
52. Ramadan RT, Ramirez R, Novosad BD, Callegan MC. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res 2006; 31: 955-65.